Table 1.
Parameter | Treatment A (CsA alone) | Treatment B (CsA + CLM) |
---|---|---|
AUC0–24 (ng•h/ml) | 6102 ± 1050 | 16879 ± 2867 a |
Cmax (ng/ml) | 553 ± 99 | 1258 ± 201 b |
tmax (h) | 2.38 ± 1.25 | 4.00 ± 0 |
t1/2 (h) | 19.24 ± 4.82 | 14.31 ± 0.65 |
C12 (ng/ml) | 218 ± 42 | 710 ± 132 c |
C24 (ng/ml) | 133 ± 14 | 400 ± 84 d |
AUMC0–24 (ng•h2/ml) | 56749 ± 9932 | 172833 ± 32848 e |
MRT0–24 (h) | 9.36 ± 0.45 | 10.16 ± 0.25 |
In this study, the dosage of CsA and CLM were adjusted to 5 mg/kg and approximately 10 mg/kg (range; 7.96–11.11 mg/kg according to the capsule strength and cat’s weight), respectively. Values are presented as means ± SE
C12 and C24 = CsA blood concentrations at 12 h and 24 h after CsA intake, respectively
Statistically different from treatment group A (P < 0.02, P < 0.03, P < 0.02, P < 0.04 and P < 0.02, respectively).